C. Randal Mills, Ph.D., President and Chief Executive Officer, joined Osiris in July 2004. Dr. Mills is also a member of the Board of Directors. Prior to joining Osiris, Dr. Mills was an executive officer of Regeneration Technologies, Inc. (NASDAQ - RTIX). Dr. Mills served in several leadership positions at RTI from its formation in 1998 until 2004, including Vice President of Business Development and Vice President of Operations and R&D and is credited with several key initiatives, including the development and commercialization of RTI’s core technology, BioCleanse®. Prior to RTI, Dr. Mills was a member of the founding management team of the University of Florida Tissue Bank, Inc. The University of Florida Tissue Bank was the predecessor company to RTI. Dr. Mills received a Bachelors degree in microbiology and cell science, and a Ph.D. in drug development, both from the University of Florida.
Philip R. Jacoby, Jr., Chief Financial Officer and Corporate Secretary, joined Osiris in April 2005. Mr. Jacoby previously served as the Company’s Controller and Chief Accounting Officer. From 1999 to 2004, Mr. Jacoby served as Vice President and Corporate Controller for FTI Consulting, Inc., a global business financial and economic consulting firm. Mr. Jacoby began his career with Arthur Andersen & Co., and earned his undergraduate degree in business and public administration from the University of Maryland.
Michelle LeRoux Williams, Ph.D., Chief Scientific Officer, joined Osiris in October 2001. Previously at Osiris, Dr. Williams served as Director of Orthopedics. In that role Dr. Williams was responsible for the development of Osteocel from initial concept through market launch. In 2005, Osteocel became the world’s first commercially available stem cell product. Additionally, Dr. Williams advanced the Chondrogen program from preclinical testing through human clinical evaluation. Prior to joining Osiris, Dr. Williams completed an NIH postdoctoral fellowship in tissue engineering at Columbia University, evaluating cellular constructs for the repair and regeneration of cartilage in arthritis patients. Dr. Williams earned a Bachelors degree in mechanical engineering from Rice University and a Ph.D. in biomedical engineering from Duke University.
Lode Debrabandere, Ph.D., Chief Operating Officer, joined Osiris in July 2006. Prior to joining Osiris, Dr. Debrabandere served for over four years with Bristol-Myers Squibb as Vice President of Strategic Marketing for Neuroscience and Infectious Diseases. He led the Neuroscience Unit and was the Global Brand Leader for Abilify™. Previously, Dr. Debrabandere led the Marketing department of UCB Pharma Inc., focusing in the areas of allergy/respiratory (Zyrtec™) and neurology (Keppra™). Dr. Debrabandere earned an MBA, a Ph.D. in pharmaceutical sciences, toxicology, and a Pharm. D. degree, all from the University of Leuven, Belgium.
Christopher R. Alder, J.D., Chief Intellectual Property Counsel, joined Osiris in April 2008. From 2001-2008, Mr. Alder served as Patent Counsel representing Panacos Pharmaceuticals & Pfizer (including lineage companies Pharmacia & G.D. Searle) where he supported multiple commercial products including Celebrex® , Bextra® & Inspra®. Mr. Alder earned his undergraduate degree in chemistry from Marshall University & his law degree from Washington University in St. Louis.